The Bracken Group names new partner
10 September 2021 -

The Bracken Group, a consultancy focused on biopharmaceutical life sciences, announced on Thursday that it has named Andrew M Salzman, MD as its new partner.

Dr Salzman trained as a paediatrician and has a Doctor of Medicine degree from Harvard following undergraduate studies in psychology at Yale. He has served as a paediatrician and professor of paediatrics and has founded and headed various companies in the life sciences sector. He has co-authored more than 170 peer-reviewed articles and has 47 patents.

Dr Salzman has also invented and developed the first clinical-stage PARP-1 inhibitor. His work is concentrated on cannabinoids and supporting organisations in the development of products in this field.

Dr Colin G Miller, co-founder and managing partner of The Bracken Group, said, 'We have had the pleasure of collaborating with Andy in the past and so were delighted when he elected to join us. His long and diverse experience as a physician, scientist, entrepreneur, and executive make Andy an extraordinary resource for the clients that The Bracken Group typically serves.'